- Home
- LDP vs PCRX Comparison
LDP vs PCRX Comparison
Compare LDP & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDP
- PCRX
- Stock Information
- Founded
- LDP 2012
- PCRX 2006
- Country
- LDP United States
- PCRX United States
- Employees
- LDP N/A
- PCRX N/A
- Industry
- LDP Finance Companies
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- LDP Finance
- PCRX Health Care
- Exchange
- LDP Nasdaq
- PCRX Nasdaq
- Market Cap
- LDP 599.3M
- PCRX 1.2B
- IPO Year
- LDP N/A
- PCRX 2011
- Fundamental
- Price
- LDP $20.86
- PCRX $26.59
- Analyst Decision
- LDP
- PCRX Buy
- Analyst Count
- LDP 0
- PCRX 10
- Target Price
- LDP N/A
- PCRX $29.30
- AVG Volume (30 Days)
- LDP 102.5K
- PCRX 892.8K
- Earning Date
- LDP 01-01-0001
- PCRX 02-27-2025
- Dividend Yield
- LDP 7.91%
- PCRX N/A
- EPS Growth
- LDP N/A
- PCRX N/A
- EPS
- LDP N/A
- PCRX N/A
- Revenue
- LDP N/A
- PCRX $694,957,000.00
- Revenue This Year
- LDP N/A
- PCRX $5.14
- Revenue Next Year
- LDP N/A
- PCRX $2.44
- P/E Ratio
- LDP N/A
- PCRX N/A
- Revenue Growth
- LDP N/A
- PCRX 4.40
- 52 Week Low
- LDP $16.16
- PCRX $11.16
- 52 Week High
- LDP $20.30
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- LDP 58.96
- PCRX 77.75
- Support Level
- LDP $20.11
- PCRX $25.06
- Resistance Level
- LDP $20.96
- PCRX $27.10
- Average True Range (ATR)
- LDP 0.21
- PCRX 1.45
- MACD
- LDP 0.06
- PCRX 0.28
- Stochastic Oscillator
- LDP 81.50
- PCRX 86.23
About LDP Cohen & Steers Limited Duration Preferred and Income Fund Inc.
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.